[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gpc3-targeted-petct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gpc3-targeted-petct":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100645208",false,"NCT07677774","GPC3-Targeted PET\u002FCT in Hepatocellular Carcinoma","Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report);\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET\u002FCT in patients with suspected or histologically\u002Fclinically confirmed hepatocellular carcinoma, and to compare with 18F-FDG PET\u002FCT.",[26,27,28],"Hepatocellular Carcinoma (HCC)","Glypican-3","GPC3-targeted PET\u002FCT",[30,27,28,31,32],"Hepatocellular Carcinoma","HCC","PET\u002FCT","RECRUITING","2026-06-25",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2026-05-01",{"date":41,"type":20},"2028-05-31",{"name":43,"class":44},"The First Affiliated Hospital of Xiamen University","OTHER",""]